<p>Comerica Bank 在最近向证券交易委员会的披露中表示，在第四季度将其在 PROCEPT BioRobotics Corporation (NASDAQ:PRCT - 免费报告) 的持股减少了 95.5%。该公司在此期间出售了 368,841 股后，持有 17,575 股。根据其最近的 SEC 文件，Comerica Bank 在 PROCEPT BioRobotics 的持股价值为 553,000 美元。</p>
<ul>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
<p>其他几家机构投资者也最近增持或减持了该公司的股份。Inscription Capital LLC 在第四季度新购入了 PROCEPT BioRobotics 的股份，价值约 537,000 美元。瑞银集团 (UBS Group AG) 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 11.5%。瑞银集团目前持有 1,052,944 股该公司的股票，价值 33,126,000 美元，此前在此期间又购买了 108,399 股。B. Metzler seel. Sohn &amp; Co. AG 在第四季度新购入了 PROCEPT BioRobotics 的股份，价值约 1,864,000 美元。苏黎世州立银行 (Zurcher Kantonalbank Zurich Cantonalbank) 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 8.8%。苏黎世州立银行目前持有 18,591 股该公司的股票，价值 585,000 美元，此前在此期间又购买了 1,502 股。最后，未来资产全球投资公司 (Mirae Asset Global Investments Co. Ltd.) 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 9.0%。未来资产全球投资公司目前持有 10,519 股该公司的股票，价值 331,000 美元，此前在此期间又购买了 869 股。机构投资者和对冲基金持有该公司 89.46% 的股份。</p>
<p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
<h2>PROCEPT BioRobotics 股票上涨 4.1%</h2>
<p>PROCEPT BioRobotics 股票周二开盘价为 26.45 美元。该公司的债务与股本比率为 0.15，流动比率为 6.73，速动比率为 5.51。PROCEPT BioRobotics Corporation 的 1 年最低价为 19.35 美元，1 年最高价为 66.85 美元。该公司的市值为 15.1 亿美元，市盈率为 -14.53，贝塔系数为 0.83。该股票的 50 日移动平均价格为 25.06 美元，200 日移动平均价格为 29.17 美元。</p>
<ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
<p>PROCEPT BioRobotics (NASDAQ:PRCT - 获取免费报告) 最近一次发布财报是在 4 月 29 日，报告显示该季度每股收益为 -0.56 美元，低于分析师一致预期的 -0.55 美元，差额为 -0.01 美元。该公司该季度的收入为 8313 万美元，而分析师预期为 8052 万美元。PROCEPT BioRobotics 的股本回报率为 -27.70%，净利润率为 -31.82%。该公司该季度的收入较去年同期增长了 20.1%。在去年同期，该公司每股收益为 -0.45 美元。平均而言，卖方分析师预测 PROCEPT BioRobotics Corporation 本财年将发布 -1.53 美元的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>PRCT 最近成为多份研究报告的主题。Leerink Partners 将 PROCEPT BioRobotics 的目标价从 55.00 美元下调至 30.00 美元，并在 2 月 26 日的报告中给予该股票 &#34;跑赢大盘&#34; 的评级。TD Cowen 将 PROCEPT BioRobotics 的目标价从 50.00 美元下调至 34.00 美元，并在 2 月 26 日的报告中给予该股票 &#34;买入&#34; 的评级。Jefferies Financial Group 在 2 月 26 日的报告中将 PROCEPT BioRobotics 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。Wall Street Zen 在 4 月 25 日的报告中将 PROCEPT BioRobotics 的评级从 &#34;强烈卖出&#34; 上调至 &#34;卖出&#34;。最后，Truist Financial 在 2 月 27 日的报告中将 PROCEPT BioRobotics 的目标价从 47.00 美元下调至 30.00 美元，并给予该股票 &#34;买入&#34; 的评级。八位投资分析师对该股票给予了买入评级，四位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 &#34;持有&#34;，共识目标价为 41.45 美元。</p>
<ul>
<li>为什么 Intuitive Surgical 股票在医疗领域占据主导地位</li>
</ul>
<p><strong>阅读我们关于 PRCT 的最新股票报告</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，董事 Antal Rohit Desai 于 3 月 9 日购买了 98,699 股该公司的股票，交易价格为每股 24.55 美元，总交易额为 2,423,060.45 美元。交易完成后，该董事在公司持有 426,262 股，价值 10,464,732.10 美元。这笔交易代表了其持股的 30.13% 增加。该购买在向证券交易委员会提交的文件中披露，文件可通过此超链接获取。此外，执行副总裁 Kevin Waters 于 3 月 6 日出售了 6,721 股公司的股票，交易价格为每股 23.70 美元，总价值为 159,287.70 美元。出售后，该执行副总裁在公司持有 152,264 股，价值约 3,608,656.80 美元。这笔交易使其持股减少了 4.23%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士购买了价值 10,483,091 美元的 426,262 股公司股票，并出售了价值 573,466 美元的 23,229 股。17.40% 的股票由公司内部人士持有。</p>
<h2>PROCEPT BioRobotics 公司简介</h2>
<p>(免费报告)</p>
<p>PROCEPT BioRobotics, Inc 是一家医疗设备公司，专注于开发和商业化用于治疗良性前列腺增生 (BPH) 的机器人系统。该公司的技术利用精密机器人和实时成像进行微创手术，旨在减少患者恢复时间，并改善与传统外科方法相比的临床结果。</p>
<p>公司的旗舰产品 AquaBeam 机器人系统使用高速水刀选择性去除前列腺组织，同时保护周围健康结构。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 PROCEPT BioRobotics 更好的股票</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
<li>如果通胀意外向下，三只股票将受益</li>
<li>MercadoLibre 大胆投资于增长：折扣加深</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
<p>在你考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 PROCEPT BioRobotics 并不在名单上。</p>
<p>虽然 PROCEPT BioRobotics 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRCT

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Comerica Bank 已显著减少在 PROCEPT BioRobotics Corporation (NASDAQ:PRCT) 的持股比例，降幅达到 95.5%，目前持有 17,575 股，价值 553,000 美元。其他机构投资者也调整了他们的持仓，其中 UBS Group AG 和 Mirae Asset Global Investments 的增持尤为显著。PROCEPT BioRobotics 的市值为 15.1 亿美元，尽管每股收益为负（$0.56），但其年收入同比增长 20.1%。分析师对该股票的评级不一，普遍目标价为 41.45 美元</p>

<p>Comerica Bank decreased its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 95.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 17,575 shares of the company's stock after selling 368,841 shares during the period. Comerica Bank's holdings in PROCEPT BioRobotics were worth $553,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Comerica Bank 在最近向证券交易委员会的披露中表示，在第四季度将其在 PROCEPT BioRobotics Corporation (NASDAQ:PRCT - 免费报告) 的持股减少了 95.5%。该公司在此期间出售了 368,841 股后，持有 17,575 股。根据其最近的 SEC 文件，Comerica Bank 在 PROCEPT BioRobotics 的持股价值为 553,000 美元。</p>
</div><ul>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
</div><p>Several other institutional investors also recently added to or reduced their stakes in the company. Inscription Capital LLC acquired a new position in PROCEPT BioRobotics during the fourth quarter worth approximately $537,000. UBS Group AG increased its position in PROCEPT BioRobotics by 11.5% during the fourth quarter. UBS Group AG now owns 1,052,944 shares of the company's stock worth $33,126,000 after buying an additional 108,399 shares during the period. B. Metzler seel. Sohn &amp; Co. AG acquired a new position in PROCEPT BioRobotics during the fourth quarter worth approximately $1,864,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in PROCEPT BioRobotics by 8.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,591 shares of the company's stock worth $585,000 after buying an additional 1,502 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in PROCEPT BioRobotics by 9.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,519 shares of the company's stock worth $331,000 after buying an additional 869 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者也最近增持或减持了该公司的股份。Inscription Capital LLC 在第四季度新购入了 PROCEPT BioRobotics 的股份，价值约 537,000 美元。瑞银集团 (UBS Group AG) 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 11.5%。瑞银集团目前持有 1,052,944 股该公司的股票，价值 33,126,000 美元，此前在此期间又购买了 108,399 股。B. Metzler seel. Sohn &amp; Co. AG 在第四季度新购入了 PROCEPT BioRobotics 的股份，价值约 1,864,000 美元。苏黎世州立银行 (Zurcher Kantonalbank Zurich Cantonalbank) 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 8.8%。苏黎世州立银行目前持有 18,591 股该公司的股票，价值 585,000 美元，此前在此期间又购买了 1,502 股。最后，未来资产全球投资公司 (Mirae Asset Global Investments Co. Ltd.) 在第四季度将其在 PROCEPT BioRobotics 的持股增加了 9.0%。未来资产全球投资公司目前持有 10,519 股该公司的股票，价值 331,000 美元，此前在此期间又购买了 869 股。机构投资者和对冲基金持有该公司 89.46% 的股份。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
</div><h2>PROCEPT BioRobotics Stock Up 4.1%</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票上涨 4.1%</h2>
</div><p>PROCEPT BioRobotics stock opened at $26.45 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. PROCEPT BioRobotics Corporation has a 1-year low of $19.35 and a 1-year high of $66.85. The company has a market cap of $1.51 billion, a PE ratio of -14.53 and a beta of 0.83. The stock's 50 day moving average price is $25.06 and its 200 day moving average price is $29.17.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics 股票周二开盘价为 26.45 美元。该公司的债务与股本比率为 0.15，流动比率为 6.73，速动比率为 5.51。PROCEPT BioRobotics Corporation 的 1 年最低价为 19.35 美元，1 年最高价为 66.85 美元。该公司的市值为 15.1 亿美元，市盈率为 -14.53，贝塔系数为 0.83。该股票的 50 日移动平均价格为 25.06 美元，200 日移动平均价格为 29.17 美元。</p>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.01). The firm had revenue of $83.13 million for the quarter, compared to analysts' expectations of $80.52 million. PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The firm's revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.45) earnings per share. On average, sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics (NASDAQ:PRCT - 获取免费报告) 最近一次发布财报是在 4 月 29 日，报告显示该季度每股收益为 -0.56 美元，低于分析师一致预期的 -0.55 美元，差额为 -0.01 美元。该公司该季度的收入为 8313 万美元，而分析师预期为 8052 万美元。PROCEPT BioRobotics 的股本回报率为 -27.70%，净利润率为 -31.82%。该公司该季度的收入较去年同期增长了 20.1%。在去年同期，该公司每股收益为 -0.45 美元。平均而言，卖方分析师预测 PROCEPT BioRobotics Corporation 本财年将发布 -1.53 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>PRCT has been the topic of a number of recent research reports. Leerink Partners dropped their target price on PROCEPT BioRobotics from $55.00 to $30.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday, February 26th. TD Cowen dropped their target price on PROCEPT BioRobotics from $50.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, February 26th. Jefferies Financial Group lowered PROCEPT BioRobotics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 26th. Wall Street Zen raised PROCEPT BioRobotics from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a report on Saturday, April 25th. Finally, Truist Financial dropped their target price on PROCEPT BioRobotics from $47.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, February 27th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $41.45.</p>
<div class="lb-trans"><p>PRCT 最近成为多份研究报告的主题。Leerink Partners 将 PROCEPT BioRobotics 的目标价从 55.00 美元下调至 30.00 美元，并在 2 月 26 日的报告中给予该股票 &#34;跑赢大盘&#34; 的评级。TD Cowen 将 PROCEPT BioRobotics 的目标价从 50.00 美元下调至 34.00 美元，并在 2 月 26 日的报告中给予该股票 &#34;买入&#34; 的评级。Jefferies Financial Group 在 2 月 26 日的报告中将 PROCEPT BioRobotics 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。Wall Street Zen 在 4 月 25 日的报告中将 PROCEPT BioRobotics 的评级从 &#34;强烈卖出&#34; 上调至 &#34;卖出&#34;。最后，Truist Financial 在 2 月 27 日的报告中将 PROCEPT BioRobotics 的目标价从 47.00 美元下调至 30.00 美元，并给予该股票 &#34;买入&#34; 的评级。八位投资分析师对该股票给予了买入评级，四位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 &#34;持有&#34;，共识目标价为 41.45 美元。</p>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Intuitive Surgical 股票在医疗领域占据主导地位</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on PRCT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 PRCT 的最新股票报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, Director Antal Rohit Desai bought 98,699 shares of the firm's stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $24.55 per share, for a total transaction of $2,423,060.45. Following the completion of the transaction, the director owned 426,262 shares in the company, valued at $10,464,732.10. This trade represents a 30.13% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Kevin Waters sold 6,721 shares of the business's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $23.70, for a total value of $159,287.70. Following the sale, the executive vice president owned 152,264 shares in the company, valued at approximately $3,608,656.80. The trade was a 4.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have bought 426,262 shares of company stock worth $10,483,091 and have sold 23,229 shares worth $573,466. 17.40% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Antal Rohit Desai 于 3 月 9 日购买了 98,699 股该公司的股票，交易价格为每股 24.55 美元，总交易额为 2,423,060.45 美元。交易完成后，该董事在公司持有 426,262 股，价值 10,464,732.10 美元。这笔交易代表了其持股的 30.13% 增加。该购买在向证券交易委员会提交的文件中披露，文件可通过此超链接获取。此外，执行副总裁 Kevin Waters 于 3 月 6 日出售了 6,721 股公司的股票，交易价格为每股 23.70 美元，总价值为 159,287.70 美元。出售后，该执行副总裁在公司持有 152,264 股，价值约 3,608,656.80 美元。这笔交易使其持股减少了 4.23%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士购买了价值 10,483,091 美元的 426,262 股公司股票，并出售了价值 573,466 美元的 23,229 股。17.40% 的股票由公司内部人士持有。</p>
</div><h2>PROCEPT BioRobotics Profile</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics, Inc 是一家医疗设备公司，专注于开发和商业化用于治疗良性前列腺增生 (BPH) 的机器人系统。该公司的技术利用精密机器人和实时成像进行微创手术，旨在减少患者恢复时间，并改善与传统外科方法相比的临床结果。</p>
</div><p>The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.</p>
<div class="lb-trans"><p>公司的旗舰产品 AquaBeam 机器人系统使用高速水刀选择性去除前列腺组织，同时保护周围健康结构。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>Before the Moon Base Gets Built, These 4 Companies Win</li>
<li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li>
<li>3 Stocks That Win If Inflation Surprises to the Downside</li>
<li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 PROCEPT BioRobotics 更好的股票</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
<li>如果通胀意外向下，三只股票将受益</li>
<li>MercadoLibre 大胆投资于增长：折扣加深</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 PROCEPT BioRobotics 并不在名单上。</p>
</div><p>While PROCEPT BioRobotics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PROCEPT BioRobotics 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Comerica 银行出售了 PROCEPT BioRobotics Corporation $PRCT 的股票